A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions Trial Phase 1 Completed Jan. 5, 2017
Norepinephrine Transporter Blockade as a Pathological Biomarker in Neurogenic Orthostatic Hypotension Trial N/A Completed Jan. 5, 2017
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. Trial Phase 1 Completed Jan. 5, 2017
Lubiprostone as a Treatment for Constipation in Parkinson's Disease Trial N/A Terminated Dec. 29, 2016
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Trial Phase 1 Completed Dec. 15, 2016
Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm Trial N/A Completed Dec. 4, 2016
Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease Trial Phase 1 Completed Dec. 4, 2016
Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation Trial N/A Terminated Nov. 30, 2016
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol Trial N/A Unknown Nov. 28, 2016
Benefit From the Chin Down Maneuver in the Swallowing Performance and Self-perception of Parkinson's Disease Patients Trial N/A Completed Nov. 27, 2016
Effect of Body Suspension and Tilting Exercises in Parkinson's Disease Trial N/A Completed Nov. 27, 2016
Concurrent DBS Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device Trial N/A Withdrawn Nov. 16, 2016